Autophagy in cancer

F1000Prime Reports

Volumn 7, Issue , 2015, Pages

  Zhi, Xiaoyong ^a   Zhong, Qing ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLIN 1; CELL PROTEIN; PROTEIN P53;

ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CANCER THERAPY; CARCINOGENESIS; CELL SURVIVAL; GERMLINE MUTATION; HUMAN; HUMAN CHROMOSOME; NEOPLASM; OVARY CANCER; PANCREAS ADENOCARCINOMA; PANCREAS ADENOMA; PHASE 1 CLINICAL TRIAL (TOPIC); TELANGIECTASIA; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

EID: 84922378824     PISSN: None     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P7-18     Document Type: Article

References (93)

1. Liang XH, Jackson S, Seaman M., Brown K, Kempkes B, Hibshoosh H., Levine B: Induction of autophagy and inhibition of tumorigen-esis by beclin 1. Nature 1999, 402:672-6.
2. Aita VM, Liang XH, Murty V.V., Pincus DL, Yu W, Cayanis E, Kalachikov S., Gilliam TC, Levine B: Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21. Genomics 1999, 59:59-65.
3. Laddha SV, Ganesan S, Chan C.S., White E: Mutational landscape of the essential autophagy gene BECN1 in human cancers. Mol Cancer Res 2014, 12:485-90.
4. Easton DF: How many more breast cancer predisposition genes are there? Breast Cancer Res 1999, 1:14-7.
5. Campeau PM, Foulkes WD, Tischkowitz MD: Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet 2008, 124:31-42.
6. Drost RM, Jonkers J: Preclinical mouse models for BRCA1-associated breast cancer. Br J Cancer 2009, 101:1651-7.
7. Qu X, Yu J, Bhagat G., Furuya N, Hibshoosh H, Troxel A., Rosen J, Eskelinen E, Mizushima N., Ohsumi Y, Cattoretti G, Levine B: Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. Journal Clin Invest 2003, 112:1809-20.
8. Yue Z, Jin S, Yang C., Levine AJ, Heintz N: Beclin 1, an autophagygene essential for early embryonic development, is a haploinsuffi-cient tumor suppressor. Proc Natl Acad Sci USA 2003, 100:15077-82.
9. Lebovitz CB, Bortnik SB, Gorski SM: Here, there be dragons: charting autophagy-related alterations in human tumors. Clin Cancer Res 2012, 18:1214-26.
10. Sato T, Nakashima A, Guo L., Coffman K, Tamanoi F: Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene 2010, 29:2746-52.
11. Hardt M, Chantaravisoot N, Tamanoi F: Activating mutations of TOR (target of rapamycin). Genes Cells 2011, 16:141-51.
12. An CH, Kim MS, Yoo N.J., Park SW, Lee SH: Mutational and expressional analyses of ATG5, an autophagy-related gene, in gastrointestinal cancers. Pathol Res Pract 2011, 207:433-7.
13. Kang MR, Kim MS, Oh J.E., Kim YR, Song SY, Kim SS, Ahn C.H., Yoo NJ, Lee SH: Frameshift mutations of autophagy-related genes ATG2B, ATG5, ATG9B and ATG12 in gastric and colorectal cancers with microsatellite instability. J Pathol 2009, 217:702-6.
14. Qu X, Zou Z, Sun Q., Luby-Phelps K, Cheng P, Hogan R.N., Gilpin C., Levine B: Autophagy gene-dependent clearance of apoptotic cells during embryonic development. Cell 2007, 128:931-46.
15. Kuma A, Hatano M, Matsui M., Yamamoto A, Nakaya H, Yoshimori T., Ohsumi Y, Tokuhisa T, Mizushima N: The role of autophagy during the early neonatal starvation period. Nature 2004, 432:1032-6.
16. Komatsu M, Waguri S, Ueno T., Iwata J, Murata S, Tanida I., Ezaki J, Mizushima N, Ohsumi Y., Uchiyama Y, Kominami E, Tanaka K, Chiba T: Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. J Cell Biol 2005, 169:425-34.
17. Takamura A, Komatsu M, Hara T., Sakamoto A, Kishi C, Waguri S., Eishi Y, Hino O, Tanaka K., Mizushima N: Autophagy-deficient mice develop multiple liver tumors. Genes Dev 2011, 25:795-800.
18. Rosenfeldt MT, O'Prey J, Morton JP, Nixon C, MacKay G., Mrowinska A, Au A, Rai T.S., Zheng L., Ridgway R, Adams PD, Anderson KI, Gottlieb E, Sansom OJ, Ryan KM: p53 status determines the role of autophagy in pancreatic tumour development. Nature 2013, 504:296-300.
19. Rao S, Tortola L, Perlot T., Wirnsberger G, Novatchkova M, Nitsch R., Sykacek P, Frank L, Schramek D., Komnenovic V, Sigl V, Aumayr K, Schmauss G, Fellner N, Handschuh S, Glösmann M, Pasierbek P, Schlederer M, Resch GP, Ma Y, Yang H, Popper H, Kenner L, Kroemer G, Penninger JM: A dual role for autophagy in a murine model of lung cancer. Nat Commun 2014, 5:3056.
20. Vinod V, Padmakrishnan CJ, Vijayan B, Gopala S: 'How can I halt thee?' The puzzles involved in autophagic inhibition. Pharmacol Res 2014, 82:1-8.
21. Yang S, Wang X, Contino G., Liesa M, Sahin E, Ying H., Bause A, Li Y, Stommel J.M., Dell'antonio G, Mautner J, Tonon G, Haigis M, Shirihai OS, Doglioni C, Bardeesy N, Kimmelman AC: Pancreatic cancers require autophagy for tumor growth. Genes Dev 2011, 25:717-29.
22. Guo JY, Karsli-Uzunbas G, Mathew R., Aisner SC, Kamphorst JJ, Strohecker AM, Chen G, Price S., Lu W, Teng X, Snyder E., Santanam U, Dipaola RS, Jacks T, Rabinowitz JD, White E: Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev 2013, 27:1447-61.
23. Strohecker AM, Guo JY, Karsli-Uzunbas G, Price S.M., Chen GJ, Mathew R, McMahon M, White E: Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors. Cancer Discov 2013, 3:1272-85.
24. Wei H, Wei S, Gan B., Peng X, Zou W, Guan J: Suppression of autophagy by FIP200 deletion inhibits mammary tumorigen-esis. Genes Dev 2011, 25:1510-27.
25. Solomon VR, Lee H: Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur J Pharmacol 2009, 625:220-33.
26. Ávalos Y, Canales J., Bravo-Sagua R, Criollo A, Lavandero S., Quest, Andrew FG: Tumor suppression and promotion by autophagy. BioMed Res Int 2014, 2014:603980.
27. Jiang P, Mizushima N: Autophagy and human diseases. Cell Res 2014, 24:69-79.
28. Rosenfeld MR, Ye X, Supko J.G., Desideri S., Grossman SA, Brem S, Mikkelson T, Wang D., Chang YC, Hu J, McAfee Q, Fisher J., Troxel AB, Piao S, Heitjan DF, Tan K, Pontiggia L, O'Dwyer PJ, Davis LE, Amaravadi RK: A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy 2014, 10:1359-68.
29. Mahalingam D, Mita M, Sarantopoulos J., Wood L, Amaravadi RK, Davis L.E., Mita AC, Curiel TJ, Espitia CM, Nawrocki S.T., Giles FJ, CarewJS: Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. Autophagy 2014, 10:1403-14.
30. Vogl DT, Stadtmauer EA, Tan K, Heitjan D.F., Davis LE, Pontiggia L, Rangwala R, Piao S., Chang YC, Scott EC, Paul TM, Nichols C.W., Porter DL, Kaplan J, Mallon G, Bradner JE, Amaravadi RK: Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy 2014, 10:1380-90.
31. Rangwala R, Chang YC, Hu J, Algazy K.M., Evans TL, Fecher LA, Schuchter LM, Torigian D.A., Panosian JT, Troxel AB, Tan K, Heitjan D.F., DeMichele AM, Vaughn DJ, Redlinger M, Alavi A, Kaiser J, Pontiggia L, Davis LE, O'Dwyer PJ, Amaravadi RK Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy 2014, 10:1391-402.
32. Rangwala R, Leone R, Chang Y.C., Fecher LA, Schuchter LM, Kramer A, Tan K., Heitjan DF, Rodgers G, Gallagher M, Piao S., Troxel AB, Evans TL, DeMichele AM, Nathanson KL, O'Dwyer PJ, Kaiser J, Pontiggia L, Davis LE, Amaravadi RK: Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy 2014, 10:1369-79.
33. Yang A, Rajeshkumar NV, Wang X, Yabuuchi S., Alexander BM, Chu GC, Von Hoff, Daniel D, Maitra A., Kimmelman AC: Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations. Cancer Discov 2014, 4:905-13.
34. Rao R, Balusu R, Fiskus W., Mudunuru U, Venkannagari S, Chauhan L., Smith JE, Hembruff SL, Ha K, Atadja P., Bhalla KN: Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells. Mol Cancer Ther 2012, 11:973-83.
35. Selvakumaran M, Amaravadi RK, Vasilevskaya I.A., O'Dwyer PJ: Autophagy inhibition sensitizes colon cancer cells to anti-angiogenic and cytotoxic therapy. Clin Cancer Res 2013, 19:2995-3007.
36. Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Corominas-Faja B, Cuyàs E, López-Bonet E, Martin-Castillo B, Joven J, Menendez JA: The anti-malarial chloroquine overcomes primary resistance and restores sensitivity to trastuzumab in HER2-positive breast cancer. Sci Rep 2013, 3:2469.
37. Shen J, Zheng H, Ruan J., Fang W, Li A, Tian G., Niu X, Luo S, Zhao P: Autophagy inhibition induces enhanced proapoptotic effects of ZD6474 in glioblastoma. Br J Cancer 2013, 109:164-71.
38. Hu Y, DeLay M, Jahangiri A., Molinaro AM, Rose SD, Carbonell WS, Aghi MK: Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma. Cancer Res 2012, 72:1773-83.
39. Godbole AM, Purushottamachar P, Martin M.S., Daskalakis C., Njar Vincent CO: Autophagy inhibition synergistically enhances anticancer efficacy of RAMBA, VN/12-1 in SKBR-3 cells, and tumor xenografts. Mol Cancer Ther 2012, 11:898-908.
40. Saleem A, Dvorzhinski D, Santanam U., Mathew R, Bray K, Stein M., White E, Dipaola RS: Effect of dual inhibition of apoptosis and autophagy in prostate cancer. Prostate 2012, 72:1374-81.
41. Shimizu S, Takehara T, Hikita H., Kodama T, Tsunematsu H, Miyagi T., Hosui A, Ishida H, Tatsumi T., Kanto T, Hiramatsu N, Fujita N, Yoshimori T, Hayashi N: Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. Int J Cancer 2012, 131:548-57.
42. Guo X, Li D, Hu F., Song J, Zhang S, Deng W., Sun K, Zhao Q, Xie X., Song Y, Wu M, Wei L: Targeting autophagy potentiates chemotherapy-induced apoptosis and proliferation inhibition in hepatocarcinoma cells. Cancer Lett 2012, 320:171-9.
43. Ding Z, Hui B, Shi Y., Zhou J, Peng Y, Gu C., Yang H, Shi G, Ke A., Wang X, Song K, Dai Z, Shen Y, Fan J: Autophagy activation in hepatocellular carcinoma contributes to the tolerance of oxaliplatin via reactive oxygen species modulation. Clin Cancer Res 2011, 17:6229-38.
44. Shi Y, Ding Z, Zhou J., Hui B, Shi G, Ke A., Wang X, Dai Z, Peng Y., Gu C, Qiu S, Fan J: Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. Autophagy 2011, 7:1159-72.
45. Mirzoeva OK, Hann B, Hom Y.K., Debnath J., Aftab D, Shokat K, Korn WM: Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K-mTOR pathway in pancreatic adenocarcinoma. J Mol Med (Berl) 2011, 89:877-89.
46. Wu Z, Chang P, Yang J.C., Chu C., Wang L, Chen N, Ma A., Desai SJ, Lo SH, Evans CP, Lam K.S., Kung H: Autophagy Blockade Sensitizes Prostate Cancer Cells towards Src Family Kinase Inhibitors. Genes Cancer 2010, 1:40-9.
47. Zinn RL, Gardner EE, Dobromilskaya I, Murphy S., Marchionni L, Hann CL, Rudin CM: Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer. Mol Cancer 2013, 12:16.
48. Zou Y, Ling Y, Sironi J., Schwartz EL, Perez-Soler R, Piperdi B: The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib. J Thorac Oncol 2013, 8:693-702.
49. McAfee Q, Zhang Z, Samanta A., Levi SM, Ma X, Piao S, Lynch J.P., Uehara T., Sepulveda AR, Davis LE, Winkler JD, Amaravadi RK: Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency. Proc Natl Acad Sci USA 2012, 109:8253-8.
50. Bristol ML, Emery SM, Maycotte P, Thorburn A., Chakradeo S, Gewirtz DA: Autophagy inhibition for chemosensitization and radiosensitization in cancer: do the preclinical data support this therapeutic strategy? J Pharmacol Exp Ther 2013, 344:544-52.
51. Kimura N, Kumamoto T, Kawamura Y., Himeno T, Nakamura K, Ueyama H., Arakawa R: Expression of autophagy-associated genes in skeletal muscle: an experimental model of chloroquine-induced myopathy. Pathobiology 2007, 74:169-76.
52. Donohue E, Thomas A, Maurer N., Manisali I, Zeisser-Labouebe M, Zisman N, Anderson H.J., Ng, Sylvia SW, Webb M, Bally M, Roberge M: The autophagy inhibitor verteporfin moderately enhances the antitumor activity of gemcitabine in a pancreatic ductal adenocarcinoma model. J Cancer 2013, 4:585-96.
53. Rodriguez-Caruncho C, Bielsa Marsol I: Antimalarials in dermatology: mechanism of action, indications, and side effects. Actas Dermosifiliogr 2014, 105:243-52.
54. Thomé R, Lopes, Stefanie Costa Pinto, Costa, Fabio Trindade Maranhão, Verinaud L: Chloroquine: modes of action of an undervalued drug. Immunol Lett, 153:50-7.
55. Maes H, Kuchnio A, Peric A., Moens S, Nys K, Bock K de, Quaegebeur A, Schoors S, Georgiadou M., Wouters J, Vinckier S, Vankelecom H, Garmyn M, Vion A, Radtke F, Boulanger C, Gerhardt H, Dejana E, Dewerchin M, Ghesquière B, Annaert W, Agostinis P, Carmeliet P: Tumor vessel normalization by chloroquine independent of autophagy. Cancer Cell 2014, 26:190-206.
56. Gottlieb RA, Nordberg J, Skowronski E., Babior BM: Apoptosis induced in Jurkat cells by several agents is preceded by intracellular acidification. Proc Natl Acad Sci USA 1996, 93:654-8.
57. Huang Z, Srinivasan S, Zhang J., Chen K, Li Y, Li W., Quiocho FA, Pan X: Discovering thiamine transporters as targets of chloroquine using a novel functional genomics strategy. PLoS genetics 2012, 8:e1003083.
58. Costedoat-Chalumeau N, Dunogué B, Morel N, Le Guern V, Guettrot-Imbert G: Hydroxychloroquine: a multifaceted treatment in lupus. Presse Med 2014, 43:e167-80.
59. Townsend KN, Hughson, Luke RK, Schlie K, Poon VI, Westerback A, Lum JJ: Autophagy inhibition in cancer therapy: metabolic considerations for antitumor immunity. Immunol Rev 2012, 249:176-94.
60. Parzych KR, Klionsky DJ: An overview of autophagy: morphology, mechanism, and regulation. Antioxid Redox Signal 2014, 20:460-73.
61. Dowdle WE, Nyfeler B, Nagel J., Elling RA, Liu S, Triantafellow E, Menon S., Wang Z, Honda A, Pardee G., Cantwell J, Luu C, Cornella-Taracido I, Harrington E, Fekkes P, Lei H, Fang Q, Digan ME, Burdick D, Powers AF, Helliwell SB, DAquin S, Bastien J, Wang H, Wiederschain D, Kuerth J, Bergman P, Schwalb D, Thomas J, Ugwonali S, et al.: Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo. Nat Cell Biol 2014, 16:1069-79.
62. Ronan B, Flamand O, Vescovi L., Dureuil C, Durand L, Fassy F., Bachelot M, Lamberton A, Mathieu M., Bertrand T, Marquette J, El-Ahmad Y, Filoche-Romme B, Schio L, Garcia-Echeverria C, Goulaouic H, Pasquier B: A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy. Nature Chem Biol 2014, 10:1013-9.
63. Liang C, Feng P, Ku B., Dotan I, Canaani D, Oh B., Jung JU: Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG. Nat Cell Biol 2006, 8:688-99.
64. Liang C, Lee J, Inn K., Gack MU, Li Q, Roberts EA, Vergne I, Deretic V., Feng P, Akazawa C, JungJU: Beclin1-binding UVRAG targets the class C Vps complex to coordinate autophagosome maturation and endocytic trafficking. Nat Cell Biol 2008, 10:776-87.
65. Matsunaga K, Saitoh T, Tabata K., Omori H, Satoh T, Kurotori N., Maejima I, Shirahama-Noda K, Ichimura T, Isobe T., Akira S, Noda T, Yoshimori T: Two Beclin 1-binding proteins, Atg14L and Rubicon, reciprocally regulate autophagy at different stages. Nat Cell Biol 2009, 11:385-96.
66. Zhong Y, Wang QJ, Li X, Yan Y., Backer JM, Chait BT, Heintz N, Yue Z: Distinct regulation of autophagic activity by Atg14L and Rubicon associated with Beclin 1-phosphatidylinositol-3-kinase complex. Nat Cell Biol 2009, 11:468-76.
67. Sun Q, Westphal W, Wong K.N., Tan I., Zhong Q: Rubicon controls endosome maturation as a Rab7 effector. Proc Natl Acad Sci USA 2010, 107:19338-43.
68. Sun Q, Zhang J, Fan W., Wong KN, Ding X, Chen S, Zhong Q: The RUN domain of rubicon is important for hVps34 binding, lipid kinase inhibition, and autophagy suppression. J Biol Chem 2011, 286:185-91.
69. Tabata K, Matsunaga K, Sakane A., Sasaki T, Noda T, Yoshimori T: Rubicon and PLEKHM1 negatively regulate the endocytic/autophagic pathway via a novel Rab7-binding domain. Mol Bio Cell 2010, 21:4162-72.
70. Funderburk SF, Wang QJ, Yue Z: The Beclin 1-VPS34 complex-at the crossroads of autophagy and beyond. Trends Cell Biol 2010, 20:355-62.
71. Sun Q, Fan W, Chen K., Ding X, Chen S, Zhong Q: Identification of Barkor as a mammalian autophagy-specific factor for Beclin 1 and class III phosphatidylinositol 3-kinase. Proc Natl Acad Sci USA 2008, 105:19211-6.
72. Itakura E, Kishi C, Inoue K., Mizushima N: Beclin 1 forms two distinct phosphatidylinositol 3-kinase complexes with mammalian Atg14 and UVRAG. Mol Biol Cell 2008, 19:5360-72.
73. Kim J, Kim YC, Fang C, Russell R.C., Kim JH, Fan W, Liu R, Zhong Q., Guan K: Differential regulation of distinct Vps34 complexes by AMPK in nutrient stress and autophagy. Cell 2013, 152:290-303.
74. Itakura E, Kishi-Itakura C, Mizushima N: The hairpin-type tail-anchored SNARE syntaxin 17 targets to autophagosomes for fusion with endosomes/lysosomes. Cell 2012, 151:1256-69.
75. Takáts S, Nagy P, Varga Á, Pircs K, Kárpáti M, Varga K, Kovács AL, Hegedlèls K, Juhász G: Autophagosomal Syntaxin17-dependent lysosomal degradation maintains neuronal function in Dro-sophila. J Cell Biol 2013, 201:531-9.
76. Karsli-Uzunbas G, Guo JY, Price S, Teng X., Laddha SV, Khor S, Kalaany NY, Jacks T, Chan C.S., Rabinowitz JD, White E: Autophagy is required for glucose homeostasis and lung tumor maintenance. Cancer Discov 2014, 4:914-27.
77. Shoji-Kawata S, Sumpter R, Leveno M., Campbell GR, Zou Z, Kinch L, Wilkins A.D., Sun Q., Pallauf K, MacDuff D, Huerta C., Virgin HW, Helms JB, Eerland R, Tooze SA, Xavier R, Lenschow DJ, Yamamoto A, King D, Lichtarge O, Grishin NV, Spector SA, Kaloyanova DV, Levine B: Identification of a candidate therapeutic autophagy-inducing peptide. Nature 2013, 494:201-6.
78. Liu Y, Shoji-Kawata S, Sumpter R.M., Wei Y., Ginet V, Zhang L, Posner B., Tran KA, Green DR, Xavier RJ, Shaw S.Y., Clarke, Peter GH, Puyal J, Levine B: Autosis is a Na+,K+-ATPase-regulated form of cell death triggered by autophagy-inducing peptides, starvation, and hypoxia-ischemia. Proc Natl Acad Sci USA 2013, 110:20364-71.
79. Huo Y, Cai H, Teplova I., Bowman-Colin C, Chen G, Price S., Barnard N, Ganesan S, Karantza V., White E, Xia B: Autophagy opposes p53-mediated tumor barrier to facilitate tumorigen-esis in a model of PALB2-associated hereditary breast cancer. Cancer Discov 2013, 3:894-907.
80. Valentin-Vega YA, Maclean KH, Tait-Mulder J, Milasta S., Steeves M, Dorsey FC, Cleveland J.L., Green DR, Kastan MB: Mitochondrial dysfunction in ataxia-telangiectasia. Blood 2012, 119:1490-500.
81. Lozy F, Cai-McRae X, Teplova I., Price S, Reddy A, Bhanot G., Ganesan S, Vazquez A, Karantza V: ERBB2 overexpression suppresses stress-induced autophagy and renders ERBB2-induced mammary tumorigenesis independent of monoalle-lic Becn1 loss. Autophagy 2014, 10:662-76.
82. Takahashi Y, Coppola D, Matsushita N., Cualing HD, Sun M, Sato Y, Liang C., Jung JU, Cheng JQ, Mulé JJ, Pledger WJ, Wang H: Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nat Cell Biol 2007, 9:1142-51.
83. Takahashi Y, Hori T, Cooper T.K., Liao J., Desai N, Serfass JM, Young M.M., Park S., Izu Y, Wang H: Bif-1 haploinsufficiency promotes chromosomal instability and accelerates Myc-driven lymphomagenesis via suppression of mitophagy. Blood 2013, 121:1622-32.
84. Mariño G, Salvador-Montoliu N, Fueyo A., Knecht E, Mizushima N, López-Otín C: Tissue-specific autophagy alterations and increased tumorigenesis in mice deficient in Atg4C/autopha-gin-3. J Biol Chem 2007, 282:18573-83.
85. Maclean KH, Dorsey FC, Cleveland J.L., Kastan MB: Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. J Clin Invest 2008, 118:79-88.
86. Loehberg CR, Thompson T, Kastan M.B., Maclean KH, Edwards DG, Kittrell FS, Medina D, Conneely O.M., O'Malley BW: Ataxia telangiectasia-mutated and p53 are potential mediators of chloroquine-induced resistance to mammary carcinogenesis. Cancer Res 2007, 67:12026-33.
87. Amaravadi RK, Yu D, Lum J.J., Bui T., Christophorou MA, Evan GI, Thomas-Tikhonenko A, Thompson CB: Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 2007, 117:326-36.
88. Kim EL, Wüstenberg R, Rübsam A, Schmitz-Salue C, Warnecke G, Bücker E, Pettkus N., Speidel D, Rohde V, Schulz-Schaeffer W, Deppert W, Giese A: Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells. Neuro-oncology 2010, 12:389-400.
89. Tuomela J, Sandholm J, Kauppila J.H., Lehenkari P., Harris KW, Selander KS: Chloroquine has tumor-inhibitory and tumor-promoting effects in triple-negative breast cancer. Oncol Lett 2013, 6:1665-72.
90. Sasaki K, Tsuno NH, Sunami E, Kawai K., Hongo K, Hiyoshi M, Kaneko M., Murono K, Tada N, Nirei T., Takahashi K, Kitayama J: Resistance of colon cancer to 5-fluorouracil may be overcome by combination with chloroquine, an in vivo study. Anticancer Drugs 2012, 23:675-82.
91. Liang X, De Vera, Michael E, Buchser W.J., Romo de Vivar Chavez, Antonio, Loughran P, Beer Stolz D, Basse P, Wang T, van Houten B, Zeh HJ, Lotze MT: Inhibiting systemic autophagy during interleukin 2 immunotherapy promotes long-term tumor regression. Cancer Res 2012, 72:2791-801.
92. Jiang P, Zhao Y, Deng X., Mao Y, Shi W, Tang Q., Li Z, Zheng Y, Yang S., Wei Y: Antitumor and antimetastatic activities of chloroquine diphosphate in a murine model of breast cancer. Biomed Pharmacother 2010, 64:609-14.
93. Carew JS, Medina EC, Esquivel J.A., Mahalingam D., Swords R, Kelly K, Zhang H., Huang P, Mita AC, Mita M.M., Giles FJ, Nawrocki ST: Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation. J Cell Mol Med 2010, 14:2448-59.